Literature DB >> 14752241

A study of VEGF and its receptors in two rat models of proteinuria.

John Kanellis1, Vicki Levidiotis, Tiffany Khong, Alison J Cox, Steven A Stacker, Richard E Gilbert, Mark E Cooper, David A Power.   

Abstract

BACKGROUND: The high level of expression of vascular endothelial growth factor (VEGF) in normal podocyte foot processes suggests that VEGF has an important role in maintaining normal glomerular function. While altered VEGF expression occurs in many glomerular diseases, a direct role for VEGF in the pathogenesis of proteinuria has not been demonstrated.
METHODS: Expression of VEGF and its receptors (VEGFR-1 and VEGFR-2) was examined in passive Heymann nephritis (PHN) and puromycin aminonucleoside nephrosis (PAN), by immunohistochemistry, in situ hybridization, Northern and Western blotting. Inhibition of VEGF in the PAN model was performed by administration of a blocking antibody.
RESULTS: In both models, glomeruli showed upregulation of VEGF and VEGF receptors compared to control animals. VEGF mRNA was increased most significantly (5-fold) at day 5 after induction of PHN, prior to the onset of proteinuria, with persistent upregulation (3-fold) at day 21. Increased VEGF mRNA was also seen in PAN, but it was less marked. In situ hybridization and immunohistochemistry localized VEGF predominantly to podocytes. Increased expression of VEGFR-1 and VEGFR-2 protein was seen in glomerular endothelial cells of PHN and PAN rats by immunohistochemistry, as was VEGFR-2 mRNA by in situ hybridization. Upregulation of VEGFR-1 by endothelial cells was more striking in the PAN model than PHN. Administration of a blocking antibody to rats with PAN did not affect proteinuria, creatinine clearance or sodium excretion.
CONCLUSION: The expression of VEGF and its receptors is significantly increased in the PHN and PAN rat models of proteinuria suggesting a role for VEGF in the disease process. VEGF may have an important role in promoting glomerular repair in a variety of glomerular diseases. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14752241     DOI: 10.1159/000075577

Source DB:  PubMed          Journal:  Nephron Physiol        ISSN: 1660-2137


  7 in total

Review 1.  Experimental membranous nephropathy redux.

Authors:  Andrey V Cybulsky; Richard J Quigg; David J Salant
Journal:  Am J Physiol Renal Physiol       Date:  2005-10

Review 2.  Aflibercept (VEGF Trap): one more double-edged sword of anti-VEGF therapy for cancer?

Authors:  Ketao Jin; Yanping Shen; Kuifeng He; Zhenzhen Xu; Guangliang Li; Lisong Teng
Journal:  Clin Transl Oncol       Date:  2010-08       Impact factor: 3.405

3.  Vascular endothelial growth factor increases the ultrafiltration coefficient in isolated intact Wistar rat glomeruli.

Authors:  Andrew H J Salmon; Christopher R Neal; David O Bates; Steven J Harper
Journal:  J Physiol       Date:  2005-10-20       Impact factor: 5.182

4.  GIV/girdin links vascular endothelial growth factor signaling to Akt survival signaling in podocytes independent of nephrin.

Authors:  Honghui Wang; Taro Misaki; Vanessa Taupin; Akiko Eguchi; Pradipta Ghosh; Marilyn G Farquhar
Journal:  J Am Soc Nephrol       Date:  2014-07-10       Impact factor: 10.121

5.  A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours.

Authors:  I Diaz-Padilla; L L Siu; M San Pedro-Salcedo; A R A Razak; A D Colevas; F A Shepherd; N B Leighl; J W Neal; A Thibault; L Liu; J Lisano; B Gao; E B Lawson; H A Wakelee
Journal:  Br J Cancer       Date:  2012-07-17       Impact factor: 7.640

Review 6.  Incidence and risk of proteinuria with aflibercept in cancer patients: a meta-analysis.

Authors:  Ling Peng; Qiong Zhao; Xianghua Ye; Yun Zhou; Danna Hu; Shusen Zheng
Journal:  PLoS One       Date:  2014-11-03       Impact factor: 3.240

7.  Yi qi qing re gao attenuates podocyte injury and inhibits vascular endothelial growth factor overexpression in puromycin aminonucleoside rat model.

Authors:  Yongli Zhan; Liping Yang; Yumin Wen; Huijie Liu; Haojun Zhang; Bin Zhu; Wenbing Han; Yanting Gu; Xueyan Sun; Xi Dong; Tingting Zhao; Huixia Ma; Ping Li
Journal:  Evid Based Complement Alternat Med       Date:  2014-05-21       Impact factor: 2.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.